These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 18271296)

  • 21. Isolation, structural elucidation and characterization of impurities in Cefdinir.
    Rao KV; Rani A; Reddy AV; Bharathi CH; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Mar; 43(4):1476-82. PubMed ID: 17174507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation, synthesis and characterization of impurities in celecoxib, a COX-2 inhibitor.
    Satyanarayana U; Rao DS; Kumar YR; Babu JM; Kumar PR; Reddy JT
    J Pharm Biomed Anal; 2004 Jun; 35(4):951-7. PubMed ID: 15193741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy.
    Rao RN; Maurya PK; Raju AN
    J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impurity profile study of dutasteride.
    Satyanarayana K; Srinivas K; Himabindu V; Mahesh Reddy G
    Pharmazie; 2007 Oct; 62(10):743-6. PubMed ID: 18236777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of amodiaquine bulk drug impurities by liquid chromatography/ion trap mass spectrometry.
    Dongre VG; Karmuse PP; Ghugare PD; Kanojiya SK; Rawal S
    Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2227-33. PubMed ID: 18543378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation and identification of a new impurity in mitoxantrone hydrochloride.
    Haiyan L
    Pharmazie; 2009 Jun; 64(6):376-9. PubMed ID: 19618673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR.
    Dongre VG; Ghugare PD; Karmuse P; Singh D; Jadhav A; Kumar A
    J Pharm Biomed Anal; 2009 May; 49(4):873-9. PubMed ID: 19201565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product.
    Mohan A; Hariharan M; Vikraman E; Subbaiah G; Venkataraman BR; Saravanan D
    J Pharm Biomed Anal; 2008 May; 47(1):183-9. PubMed ID: 18313249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification, isolation and characterization of process related impurities in ezetimibe.
    Guntupalli S; Ray UK; Murali N; Gupta PB; Kumar VJ; Satheesh D; Islam A
    J Pharm Biomed Anal; 2014 Jan; 88():385-90. PubMed ID: 24176742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification, isolation and characterization of potential degradation product in risperidone tablets.
    Bharathi Ch; Chary DK; Kumar MS; Shankar R; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Jan; 46(1):165-9. PubMed ID: 17981421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impurity profile study of zaleplon.
    Bharathi Ch; Prabahar KJ; Prasad ChS; Kumar MS; Magesh S; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 May; 44(1):101-9. PubMed ID: 17367980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of potential impurities of rabeprazole sodium.
    Reddy GM; Bhaskar BV; Reddy PP; Sudhakar P; Babu JM; Vyas K; Reddy PR; Mukkanti K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1262-9. PubMed ID: 17134865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LC determination of glimepiride and its related impurities.
    Khan MA; Sinha S; Vartak S; Bhartiya A; Kumar S
    J Pharm Biomed Anal; 2005 Oct; 39(5):928-43. PubMed ID: 16040224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR.
    Raman B; Sharma BA; Mahale G; Singh D; Kumar A
    J Pharm Biomed Anal; 2011 Sep; 56(2):256-63. PubMed ID: 21664089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR.
    Raman B; Sharma BA; Butala R; Ghugare PD; Kumar A
    J Pharm Biomed Anal; 2010 May; 52(1):73-8. PubMed ID: 20079995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural identification and characterization of potential impurities of pantoprazole sodium.
    Reddy GM; Bhaskar BV; Reddy PP; Ashok S; Sudhakar P; Babu JM; Vyas K; Mukkanti K
    J Pharm Biomed Anal; 2007 Oct; 45(2):201-10. PubMed ID: 17629653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an unknown trace-level impurity in bulk drug of Seroquel by high-performance liquid chromatography combined with mass spectrometry.
    Xu H; Wang D; Sun C; Pan Y; Zhou M
    J Pharm Biomed Anal; 2007 Jun; 44(2):414-20. PubMed ID: 17420108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique.
    Cao X; Tai Y; Sun C; Wang K; Pan Y
    J Pharm Biomed Anal; 2005 Sep; 39(1-2):39-45. PubMed ID: 16085133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
    Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparative isolation and structural elucidation of impurities in fluconazole by LC/MS/MS.
    Dongre VG; Karmuse PP; Ghugre PD; Salunke SM; Panda N; Kumar A
    J Pharm Biomed Anal; 2006 Sep; 42(3):334-40. PubMed ID: 16757140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.